Alexandra Richardson, PhD, CLP April 2015

Similar documents
leading the way in research & development

Insight to Gene Techno Science Co.,Ltd

An analysis of the Swedish Biotech Pipeline April, The Swedish Biotechnology Industry Organization

European Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York

A unique Collaborative Model for the Discovery of New Therapeutic Approaches

The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Catalog Addendum

Advanced Microbial Protein Expression

Roche in Australia Innovation Leader

Quo vadis Pharma industry. Vladimír Král, 2015

BIOCRATES Life Sciences AG Short Company Presentation

Voyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies

November 5 th, 2013 FOCUS 2014 COMPETITION

The science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway

RNA BASED THERAPEUTICS, A R&D CUTTING EDGE

Innovating out of Crisis

SSPPS STRATEGIC PLAN. Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice. April 30, Overview

Skills Required by Pharmacologists and Physiologists in Today s Pharmaceu:cal Industry

DISCOVERY AND VALIDATION OF TARGETS AND BIOMARKERS BY MASS SPECTROMETRY-BASED PROTEOMICS. September, 2011

ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless.

Drug Reposition & Open Innovation Initiatives: potential paths to new therapies and advancing medical science

Organizing committee at imed.ulisboa/ffulisboa Joao Goncalves (Coordinator) and Paula Brito.

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

BIOMEDICAL RESEARCH CENTRES

Message from Genentech s Executive Sponsor

Lecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry

Dr Amy Prosser Careers in Research: Industry

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

Inaugural Fraunhofer Delaware Technology Summit

INNOVATIVE TECHNOLOGY IN MEDICINE: EXPERIENCE OF POLAND AND UKRAINE

REIMAGINING DRUG DEVELOPMENT:

Production Assistance for Cellular Therapies PACT

STARTING STRONGER IN PHASE I THROUGH IIA

The Integrated Biomedical Sciences Graduate Program

Leading The Way in Life Science Technologies. Planning Calendar

Opportunities for industry/smes in EU-funded health research

MAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE

INTELLIGENT ANTIBODY DISCOVERY FROM HUMANS AND OTHER ANIMALS. Guy Cavet

Roche, Roche Molecular Diagnostics and more

Affinity Reagents: The Landscape and Affimer Technology Competitive Advantages

PLTW Biomedical Science Medical Interventions Course Outline

Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO

Presented by: Tess L. Crisostomo Laboratory Quality Assurance/Compliance Officer Naval Medical Center San Diego

Microbiology and Molecular Genetics

A full-service CRO with integrated early-stage capabilities

Globalization and Innovation will drive growth

Drug Discovery Pipeline Overview 2011

CUBAN BIOTECH AND PHARMACEUTICAL INDUSTRY: RESULTS AND PERSPECTIVES GROUP OF BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES

The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence

MOSAIQUES DIAGNOSTICS

Rare diseases in the 7th EU Framework Programme for Research and Technological Development

Corporate Presentation. March 2018

FDA Perspectives on Biomarkers. Steven Kozlowski, M.D. Office of Biotechnology Products OPS/CDER/FDA

Valuing and Licensing Intellectual Property. Richard Williams

Vecchi anticorpi per nuove terapie biologiche

Cytomics in Action: Cytokine Network Cytometry

B-cell Epitope Prediction and Cloning monoclonal ADAs

SMEs in IMI2 Calls for Proposals

PACT. PACT Program. Production Assistance for Cellular Therapies

Factor X. Factor IIa (thrombin)

ATIP Avenir Program 2018 Young group leader

Strategy for Selecting NAb Assay Format

Gene Silencing: A quiet revolution in healthcare

Momenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference

THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION

sirna Overview and Technical Tips

Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services

GUIDANCE ON THE EVALUATION OF NON ACCREDITED QUALIFICATIONS

Addressing attrition in neurosciences. Dr Ismail Kola Head UCB NewMedicines

Central University of Rajasthan School of Life Sciences Syllabus for the pre-phd course work for the next academic session

Doctor of Pharmacy Course Descriptions

The World Leader in SPR Technology. Jimmy Page, PhD, Biacore, Inc.

Regulatory Pathways for Rare Diseases

not to be republished NCERT BIOTECHNOLOGY AND ITS APPLICATIONS CHAPTER BIOLOGY, EXEMPLAR PROBLEMS MULTIPLE-CHOICE QUESTIONS

Innovative therapies. FIT Biotech Oy Chief Scientific Officer Santeri Kiviluoto, PhD, BSc (Econ & Bus Adm)

MedImmune Delivering the next wave of scientific innovation. Bahija Jallal, Executive Vice President, MedImmune

BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD. crohnsandcolitis.ca

OPT-302: a VEGF-C/VEGF-D Trap for wet AMD

REGENXBIO Inc. Ticker: RGNX

Dealdoc. Marketing agreement for Recombinant Human Insulin, Glargine, Aspart and Lispro biosimilars (terminated) Pfizer Biocon.

Practical Applications of Immunology (Chapter 18) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College Eastern Campus

Optimisation de votre programme de développement

Master List of Professional Electives Course Title Description Credit Hours. Note: This class only meets for the last 7 class periods of the semester.

Celerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept. San Francisco, CA Tue 8 th, Apr 2014

Konica Minolta to Acquire Invicro (US)

Euro Diagnostica ilite Cell-based Reporter Gene Assays

SYMBIOTIC HEALTH. Targeted GI Delivery of Orally Administered Cells and Proteins for Microbiome-Based Therapeutics

Course Descriptions. BIOL: Biology. MICB: Microbiology. [1]

Request for Projects for Wake Forest Brain Tumor SPORE Application

A LentiVector Platform Company, and a leader in gene and cell therapy. Annual General Meeting 23 May 2017

Biomedical Optics Instrumentation

Envigo Corporate & Industry Overview. Rutgers University

Disclaimer. 2

Investor Presentation. June 2015

0. Courses Other Information 1. The Molecules of Life 2. The Origin of Life 3. The Cell an Introduction

A look into the future - International Progressive MS Alliance. Dr Dhia Chandraratna Head of Research, MSIF

Transcription:

Alexandra Richardson, PhD, CLP April 2015

Clayton Biotechnologies, Inc. is a for-profit company which facilitates the commercialization of medical discoveries made by the Clayton Foundation for Research and its supporting entities. The Clayton Foundation for Research is a nonprofit medical research organization in Houston, Texas established in 1933 by Benjamin Clayton. The two-fold mission of the Foundation is to: conduct medical research for the purpose of discovering the cause, prevention and cure of diseases for the benefit of mankind, and transfer the resulting medical research discoveries from the laboratory to the use of the general public by patenting and licensing such technology for development into drugs or other products. 2

Medical Research at Leading Research Institutions U. of Geneva North Carolina State UCSD Salk UT-Austin UT-Southwestern MD Anderson UTHSC-San Antonio Baylor College of Medicine UT-Medical Branch 3 Medical research for the purpose of discovering the cause, prevention and cure of diseases for the benefit of mankind

Medical Research to Develop Cures Cancer CNS & Ophthalmology Metabolic Diseases Immunotoxins for targeted cancer therapy Avicin to treat Mantle cell Lymphoma Monoclonal antibodies targeting angiogenesis Stem Cell Therapy for Parkinson s Disease Modulation of brain stress in neurological diseases Urocortin peptides for diabetes GLP-1 combination therapy Engineered proteases Next generation anti-mitotic drugs Fc engineered aglycosylated antibodies Genetic disease models for neurological diseases Gene therapy and peptide therapeutics for AMD Molecular switches in glucose control Serum oxysterols as biomarkers of disease 4

Medical Research to Develop Cures Infectious Diseases Autoimmune & Inflammation Cardiology Endometriosis Vaccines for Dengue and Chinkungunya Engineered proteases Urocortin peptides and gene therapy for congestive heart failure Small molecules targeting SRC Vaccines and diagnostics for Ehrlichioses Fc engineering of aglycosylated antibodies OCT-TPL diagnostics of human vascular plaques OCT Image Guided Laser knife for diagnosis and treatment 5

Leaders in Innovation and Technology Stem Cell Therapy Examples Gene Therapy Neuropeptides Protein Engineering, Antibodies and Immunotoxins 6

Transforming Research Into Products Mission Two: To transfer the resulting medical research discoveries from the laboratory to the use of the general public by patenting and licensing such technology for development into drugs or other products. Collaborations Spin-out companies Licensing 7

Portfolio of Start-up Companies 8

Some of Our Other Licensees 9

Marketed Products Exparel DepoDur Morphine liposome injectable suspension Post-operative pain Depocyt Cytarabine liposomes injectable suspension Lymphomatous and solid tumor meningitis Attrius Retcam AccuPlex 4 SCA6 Diagnostic tests FIA 10 bupivacaine liposome injectable suspension Pain Cardiac PET Imaging Medical imaging systems for private practices Neonatal and pediatric imaging system Wide-field digital imaging system for the hospital and clinic Ehrlichoisis canine Assay for canine vector borne diseases Ataxia diagnostic Assay for Spinocerebellar ataxia type 6 (SCA6) Functional Intracellular analysis Assay for intracellular function of essential micronutrients

Clinical Pipeline Candidate compound Indication Development Stage Partner Lenti-D Childhood ALD Pre-clinical Phase I Phase II/III LentiGlobin Betathalassemia Pre-clinical Phase I/II LentiGlobin Sickle cell anemia Pre-clinical Phase I Retinostat AMD Pre-clinical Phase I Urocortin Congestive Heart Failure Pre-clinical Phase I Phase II Available to Partner VC-01 Type I Diabetes Pre-clinical Phase I 11 α-tea Breast cancer Pre-clinical Phase I A Cancer Research Hospital

Advanced Pre-clinical Pipeline Candidate compound 12 Indication Development Stage Encorstat Corneal graft rejection Pre-clinical Avicin Mantle Cell Lymphoma Pre-clinical Dengue tetra vaccine Dengue Fever IND package VEGF-rGel Solid Tumors IND package VEGF-rGel AMD Advanced pre-clinical Partner IND IND Available to Partner Available to Partner

Collaboration and Licensing Opportunities Urocortins and analogues for Diabetes GLP-1 agonist combination therapies for Diabetes Alk4-Fc, a Cripto antagonist for Cancer Granzyme B - a potent payload for antibody drug conjugates (ADC) YESS - engineering of proteases Fc engineered antibodies with specific effector function 13 Filaggrin to treat dermatological disorders TEAD gene and peptide therapies for ocular neovascular disease CRFR1 antagonists - therapeutic for early onset AD Stem cell therapy program for Parkinson's Disease Vaccines and Diagnostics for Ehrlichioses OCT guided laser knife for surgery in small spaces

Conducting and funding research Transferring research into products One Riverway, Suite 1520 Houston, Texas 77056 713.963.5860 www.claytonbiotech.com arichardson@claytonbiotech.com